Skip to content

Seung Chu

Seung Chu

Company: Xencor

Job title: Associate Director - Cell Biology


Dr. Chu has been at Xencor since 2001 and currently leads the Cell Biology Group involved in drug/target discovery and validation as well as the preclinical advancement of therapeutic molecules. He has contributed to multiple Xencor programs exploiting platforms including T cell-engaging anti-CD3 and checkpoint inhibitor bispecific antibodies and engineered cytokines. He received his Ph.D in cell and molecular biology and finished his post-doctoral training in x-ray crystallography and structural biology.


Panel Discussion: Focusing on Dosing Regimens and the Therapeutic Window in order to Develop Easily Administered Drugs 2:15 pm

• Exploring the potential ability of drugs with short serum half-lives allowing precise control of drug levels within the patient to enhance their potential safety • Determining the exposure levels needed for cell engagers to be effective • Understanding the importance of dose selection and escalation • What preclinical information is actually useful? • Do…Read more

day: Day Two

Maximizing Therapeutic Potential by Affinity and Avidity Engineering 11:00 am

• Antigen affinity optimization for increased exposure and reduced toxicity • Multi-valent antibody scaffold for avidity-mediated tumor selectivityRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.